Pfizer (PFE) Chief Executive Albert Bourla said that no agreements have been reached in recent drug pricing-related talks between the US government and pharmaceutical companies, according to a FactSet transcript of a Goldman Sachs healthcare conference Monday.
The discussions with the Trump administration were "cordial" and did not include specific proposals, Bourla said at the conference, according to the transcript.
US President Donald Trump issued an executive order on May 12 aimed at cutting US drug prices by linking them to international rates.
Bourla also said Pfizer may consider excluding some products from government reimbursement programs in European countries where prices remain low, though he said the company does not plan to pull those products from the market entirely.
"We prefer to find a solution that can motivate Europeans to do a little bit more, can motivate the pharmaceutical companies to reduce their prices, but also in a way that it's sustainable for the industry," Bourla said, the transcript showed.
Price: 23.72, Change: +0.38, Percent Change: +1.65
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.